Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
( ], R. R% S1 {7 R. q0 F% r, d& U; F; ]" `
6 p+ t' e5 R4 X5 U* G
Sub-category:
% A$ ^0 _/ D$ q! [% zMolecular Targets
# l4 M3 q) _; S2 }$ v! h
% M9 @9 ^0 a8 V, k- L$ g/ s3 H M0 k. i7 b p* n
Category:; R& a0 U" I/ E4 e+ i9 g7 v( G
Tumor Biology 6 t: P' _/ o) G7 s* N$ D0 U$ o
, V2 k" l) n/ p! e) A0 B+ n
! s% z5 Q& ~" G& aMeeting:
, D2 I k# ^8 @# Z3 m' ^6 Y2011 ASCO Annual Meeting
# C+ M$ \) j9 d# J8 f! r
; X4 h; @! U7 c6 `
) q0 [+ N" i4 K1 q. ISession Type and Session Title:
0 V2 W$ K% |+ h/ ?! k3 jPoster Discussion Session, Tumor Biology
. l# P2 [! o8 e" H [2 {# Z6 `' E* c( S* E0 p7 R
$ }2 S; \8 e. o! F3 S. u" _Abstract No:
' P( S6 j C1 }5 Z7 L10517
/ ?1 o1 r6 _4 r* Z. `- o8 I" a# [" U) A6 ~/ y
* I' S; t) e0 k. d3 f* T# Z# |$ L
Citation: V. u4 M' A& T$ |
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 k: J) m4 e! f" V( p# L) w% s& S8 f' p8 U' Z) W# c ` q0 Y
5 ~6 K7 u5 {* |+ W6 |) ~& @
Author(s):
0 G! p1 H. ~7 P" oJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
& x, n) P1 M. K' m( K7 d. b' j) `! J/ ?0 W% b% T- K1 X
) C% d s& d0 }! q
/ ?8 ~: y# }2 x; q- t4 hAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 T P' E+ V2 H9 W$ ]0 J2 g. I7 D' J3 j1 G
Abstract Disclosures9 n# r, c! ~& p2 U4 _' l
- d7 O7 w& s! I0 w" cAbstract:
7 I; a0 {1 }7 b) I$ b: b f! M; i& q: j" e b2 f" D1 E) l
0 @) R8 K5 i8 S% g7 D
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
( l2 y( N2 G W0 [0 K3 t) f
* B" c9 ?4 y& u! b0 q1 m( X5 m : i C+ Y6 \- ]) }$ W& P+ t
|